Bempedoic acid

- **MOA:** inhibits ATP-citrate lyase which results in:
  1) reduction in cholesterol synthesis
  2) increase in LDL-receptors
  3) increase in HDL levels

- **side effects:**
  1) inhibition of uric acid transporter which results in hyperuricemia and gout
  2) a decrease in Hb synthesis

Pcsk9 inhibitors

- **MOA:** inhibition of Pcsk9 that that induces LDL-receptor degredation

- **drugs:**
  1) evolocumab/alirocumab: monoclonal antibodies
  2) inclisiran: small interfering RNA (siRNA)

- **side effects:** almost none, however monoclonal antibodies may produce flue like symptoms

APoC-III inhibitors

- **MOA:** inhibition of APoC-III that inactivates LiPo Protein LiPase leading to lowering TG, VLDL, and Chylomicron levels

- **drugs:** Volanesoren (antisense oligonucleotide targeting APOC3 mRNA

- **side effects:** Thrombocytopenia and injection-site reactions

ANGPtl3 inhibitors

- **MOA:** inhibition of ANGPtl3 that inactivates lipoprotein lipase as well as endothelial lipase

- **drugs:**
  1) **Evinacumab:** a monoclonal antibody
  2) **vupanorsen:** an antisense oligonucleotide
- **side effects:** monoclonal antibodies have flue like symptoms

By thaer